Tagged Articles

Janumet 27 articles

Diabetes drugs Janumet, Kombiglyze XR get new boxed warning for lactic acidosis

New boxed warnings – the most serious warnings the Food and Drug Administration (FDA) can give – were added to the safety labels of the type 2 diabetes drugs Janumet and Kombiglyze XR, informing patients and their doctors that the drugs have been linked to cases of lactic acidosis resulting in death, hypotension, and resistant bradyarrhythmias (slow heart rate). Lactic acidosis is a medical condition in which there is a buildup of lactate in the body, resulting in an excessively low pH. A boxed warning, also called a black box warning, is applied to drugs or medical devices for which there ... Read More

Pancreatitis rate dramatically increasing in recent years

Pancreatitis, a painful inflammation of the pancreas, is the most common cause of hospitalization for patients with a gastrointestinal disorder. The number of those afflicted with the condition has nearly doubled in the past two decades, with more than 40-60 new cases per 100,000 diagnosed each year. Researchers say the cause for the increase in pancreatitis is likely linked to the growing problem of obesity, which is strongly related to gallstones, as well as increasing amounts of alcohol consumption. Pancreatitis can be acute, meaning it occurs suddenly and usually resolves within days if treated in a timely manner, or chronic, ... Read More

Newer users of non-insulin diabetes drugs at greater risk for pancreatic cancer

People who recently started using a type 2 diabetes medication from a newer class known as incretin mimetics had double the risk of pancreatic cancer compared to diabetics who did not take the medication. However, the risk dropped to baseline with prolonged use, according to a new study published in the journal Diabetes, Obesity and Metabolism. Researchers from Maastricht University Medical Center in the Netherlands conducted a retrospective population-based cohort study involving 182,428 patients with at least one non-insulin anti-diabetic drug (NIAD) prescription and matched them with a control group of patients who did not have diabetes. They also used a ... Read More

Four Dangerous Diabetes Drugs

Type 2 diabetes is a growing epidemic around the world with an estimated one in 10 adults predicted to be suffering from the disease by 2030, according to the International Diabetes Foundation. Diabetes increases the risk for serious health complications including heart disease, kidney disease, cancer, blindness, dementia and amputations from neuropathy. Many diabetics require medication to help control blood sugar levels. There are dozens of diabetes treatments on the market and more being developed. But these drugs come at a risk. Here are five type 2 diabetes drugs that carry dangerous side effects: Invokana/Invokamet – Known chemically as canagliflozin, Invokana ... Read More

New side effects added to label of type 2 diabetes drugs Tradjenta, Jentadueto

Type 2 diabetes drugs that contain the active ingredient linagliptin have updated their safety labels to warn that some patients have developed painful mouth ulcers after taking the medication, according to the Food and Drug Administration (FDA). Linagliptin is the active ingredient in the brand-name diabetes treatments Tradjenta and Jentadueto. The drugs are in a newer class of diabetes treatments know as dipeptidyl peptidase-4 inhibitors, or DPP-4. Other drugs in this class include Januvia and Janumet. These medications are in a wider class of drugs known as incretin mimetics, which includes brands such as Byetta and Victoza. Mouth ulcers are ... Read More

Novo Nordisk becomes top diabetes drug seller with Victoza

Danish drug company Novo Nordisk has become the top seller of diabetes medications thanks to its blockbuster type 2 diabetes treatment Victoza (liraglutide), which brought in a whopping $2 billion in sales, up 15 percent over last year. Novo Nordisk displaced Sanofi, which sells numerous insulin products including Lantus, insulin-delivery devices as well as the diabetes drugs Lyxumia (lixisenatide) and Amaryl/Amarel (glimepiride). Victoza was approved by the Food and Drug Administration (FDA) in 2010 and became one of the newer members of a new class of diabetes medications known as incretin mimetics. Other drugs in this class include Byetta/Bydureon (exenatide) ... Read More

Sanofi ready to submit new type 2 diabetes drug for approval

After years of delay, drug maker Sanofi is almost ready to resubmit its type 2 diabetes treatment lixisenatide for Food and Drug Administration (FDA) approval, armed with a long-term study that the company hopes will squash any safety concerns posed by FDA panel advisors. Lixisenatide, which is already approved in Europe and marketed under the name Lyxumia, is a GLP-1 agonist that works similarly to already marketed drugs Byetta and Victoza. The drug was originally under review by an FDA advisory panel in 2013, but after Novo Nordisk’s GLP-1 drug was rejected due to safety concerns, Sanofi opted to pull lixisenatide’s ... Read More

Alarming number of pancreatitis, pancreatic cancer cases with diabetes drugs

Pancreatitis is a painful inflammation of the pancreas that can increase the likelihood of a patient developing pancreatic cancer, a health problem that type 2 diabetics are already at greater risk of developing. Interestingly, a study of drug adverse event reports reveals that common type 2 diabetes drugs have been associated with side effects that include acute pancreatitis and pancreatic cancer. Health informatics firm AdverseEvents scoured through post-marketing reports filed with the Food and Drug Administration (FDA) and found 1,900 cases of pancreatitis with AstraZeneca’s Byetta injection, 1,284 cases in patients taking Novo Nordisk’s Victoza, and 1,296 cases in patients ... Read More

New adverse reaction added to Januvia, Janumet safety label

The safety label of the type 2 diabetes drugs Januvia, Janumet and Janumet XR have been updated to include a warning for pruritus, also known as itching. Pruritus can be associated with a number of disorders, including dry skin, skin disease, pregnancy, and in some cases, cancer. It has also been associated with some medications. In some cases, pruritus is accompanied with a rash. Januvia, Janumet and Janumet XR contain the active ingredient sitagliptin. Janumet and Janumet also contain the diabetes medciation metformin. These drugs belong to a class of type 2 diabetes medications known as incretin mimetics. In 2013, ... Read More

Heart health concerns lead to more studies of newer type 2 diabetes drugs

Safety concerns with newer type 2 diabetes medications has prompted a new study into cardiovascular risks in patients who use the drugs. Earlier this month, a Food and Drug Administration (FDA) advisory panel recommended that two new diabetes drugs, Onglyza and Nesina, include new information about the risk of heart failure. The drugs are in a class of medications known as incretin mimetics, which includes the brand name diabetes drugs Victoza, Byetta and Januvia. Onglyza and Nesnia share a subclass known as DPP-4 inhibitors with Januvia, and this prompted researchers to take a closer look at cardiovascular risks with Januvia. ... Read More